Alkylating drugs are therefore more effective in cancers that have low levels of MGMT, and for this reason, MGMT itself has become attractive as a drug target, since depleting its activity enhances the potency of alkylating drugs [1,7]. The gene discussed is MGMT; the disease is cancer.